Literature DB >> 7729026

Delayed improvement in exercise capacity with restoration of sinoatrial node response in patients after combined treatment with surgical repair for organic heart disease and the Maze procedure for atrial fibrillation.

J Tamai1, Y Kosakai, T Yoshioka, E Ohnishi, H Takaki, Y Okano, Y Kawashima.   

Abstract

BACKGROUND: Although the Maze procedure successfully restores sinus rhythm in patients with heart disease and atrial fibrillation, it is still uncertain whether an addition of the Maze procedure in cardiac surgery is beneficial for exercise performance of the patients after surgery. METHODS AND
RESULTS: The Maze procedure was performed in 25 patients (age, 37 to 70 years) during valve surgery (18 patients) or closure of atrial septal defect (7 patients). A cardiopulmonary exercise test using ramp incremental protocol (15 W/min) was performed before and 1 month, 6 months, and 1 year after surgery. Sinus conversion was obtained in 23 of 25 patients 1 month after surgery. However, sinoatrial (SA) node response to exercise was attenuated by surgery: Mean heart rate (HR) was 83 +/- 13/min at rest, 94 +/- 13/min at 60 W, and 107 +/- 17/min at peak exercise. Peak oxygen uptake (PVO2) was unchanged at this period (before, 17.6 +/- 4.5 mL.min-1.kg-1; 1 month after, 17.5 +/- 4.2 mL.min-1.kg-1). Thereafter, SA node response was restored 6 months after surgery: Mean HR was 84 +/- 13/min at rest, 104 +/- 16/min at 60 W, and 130 +/- 20/min at peak exercise (P < .01 versus 1 month). PVO2 was also improved at this period (20.7 +/- 4.0 mL.min-1.kg-1, P < .01). The increase in PVO2 from 1 month to 6 months after surgery was correlated with the increase in peak HR (y = 0.73x +/- 3.6, r = .79). There were no further changes in heart rate response or PVO2 from 6 months to 1 year after surgery.
CONCLUSIONS: Atrial fibrillation was successfully treated by combined treatment with surgical repair for organic heart disease and the Maze procedure. However, SA node response to exercise was attenuated early after surgery. Thus, exercise capacity was improved at the late phase after surgery, which was related to the extent of restoration in SA node response.

Entities:  

Mesh:

Year:  1995        PMID: 7729026     DOI: 10.1161/01.cir.91.9.2392

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Surgery for atrial fibrillation.

Authors:  J M McComb
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Electrocardiographic nature of restored sinus rhythm after Cox maze procedure in patients with chronic atrial fibrillation who also had other cardiac surgery.

Authors:  J Kamata; K Nakai; N Chiba; S Hosokawa; Y Sato; M Nasu; T Sasaki; H Kitahara; H Izumoto; Y Yagi; C Itoh; K Hiramori; K Kawazoe
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 3.  Sinus Node Dysfunction in Atrial Fibrillation: Cause or Effect?

Authors:  Anna Kezerashvili; Andrew K Krumerman; John D Fisher
Journal:  J Atr Fibrillation       Date:  2008-09-16

4.  Acute and chronic effects of surgical thromboendarterectomy on exercise capacity and ventilatory efficiency in patients with chronic thromboembolic pulmonary hypertension.

Authors:  T Iwase; N Nagaya; M Ando; T Satoh; F Sakamaki; S Kyotani; H Takaki; Y Goto; Y Ohkita; M Uematsu; N Nakanishi; K Miyatake
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

5.  Delayed improvement of autonomic nervous abnormality after the Maze procedure: time and frequency domain analysis of heart rate variability using 24 hour Holter monitoring.

Authors:  K Fukushima; T Emori; W Shimizu; T Kurita; N Aihara; Y Kosakai; F Isobe; K Shimomura; Y Kawashima; T Ohe
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

6.  Mechanism of improvement in exercise capacity after the maze procedure combined with mitral valve surgery.

Authors:  S Yuda; S Nakatani; Y Kosakai; T Satoh; Y Goto; M Yamagishi; K Bando; S Kitamura; K Miyatake
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.